Clinical Trial Search

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit — 12.8; 14.4; 17.6; 17.1 Number of Inflammatory Lesions — p=0.4344

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: Success Rates of the Procedure — 8; 14; 16; 11 Participants

Primary: Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers — 1801.23; 1722.83; 1778.48…

Primary: Percentage of Participants With Adverse Events (AEs) — 30.2; 39.0; 30.0 percentage of participants

Primary: Change From Baseline to Week 12, Expressed as a Ratio, in Number of Airway Submucosal Eosinophils — 1.29; 1.07 Ratio — p=0.3862

Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086

Primary: Number of Patients Alive and Progression Free After 6 Months — 1 Participants

Primary: Success Rates of the Procedure — 37; 38; 39; 30 Participants — p=0.007

Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants

Primary: Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population) — 0.38; -0.44; -3.09 percentage of fat — p=0.034

Primary: Determination of HLA Type — 15; 5; 5; 1 subjects

Primary: Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 0; 0; 2; 1 Participants

Primary: Number of Participants With Successful Transition From IV/SC Remodulin to Oral Treprostinil (Cohort 1), From Inhaled Prostacyclin to Oral Treprostinil (Cohort 2), or as…

Primary: Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169 — 59.4; 63.2; 57.4; 58.6 Percentage of participants — p=0.9745